The listing was spearheaded by Endonovo’s partner,
Expanding Distribution for FDA-Cleared Surgical Solutions
SofPulse® is an FDA-Cleared medical device which is recognized for its exceptional efficacy for postoperative reduction of pain and edema (inflammation). Clinical studies and patient use have shown that PEMF has the capacity to alleviate pain, promote recovery and enhance overall patient well-being. As SofPulse® is non-invasive, opioid-free and with its potential to speed up recovery, it sets it apart in the medical technology landscape.
The inclusion of SofPulse® on the FSS signifies not only a stamp of approval from Federal authorities, but further affirms the Company’s objective of having SofPulse® widely distributed within the government healthcare sectors.
"This endorsement reaffirms our commitment to delivering cutting-edge solutions that cater to diverse healthcare needs” according to
SofPulse® Positioned for Accelerated Revenue Growth
SofPulse® listing on the FSS places its proven PEMF recovery technology at the forefront of distribution, paving the way for exponential growth within the
“Securing a coveted place on the prestigious FSS for SofPulse® PEMF products is a significant milestone and will help us expand our distribution, growth and revenues from our government healthcare contracts,” Weisberg said.
Opportunity to Capitalize on Untapped PEMF Market
The FSS was established as a means of streamlining government purchases of commercial products. Having SofPulse® included in the FSS will provide for expanded opportunities for the distribution of the Company’s innovative PEMF products throughout the
As Endonovo navigates this new phase of Federal expansion, the Company remains resolute in its mission to enhance patient care for our military heroes and their families. Expanding Federal contracts is important to positioning Endonovo to seize anticipated expansion for active and non-active military personnel surgical, medical and wound care needs. Through the FSS, SofPulse® will gain increased visibility to serve a wider range of patients., strengthening its position as a non-opioid medical solution within the Government medical technology sector.
Plans for Future Expansion of Government Contracts
Endonovo has identified numerous governmental healthcare contracts for the expansion of distribution throughout the government healthcare sectors. Through Academy Medical, additional future government contracts targeted include: Strategic Acquisition Center (SAC), National Acquisition Center (NAC) and the defense agencies and
Weisberg concluded: “To streamline our government distribution expansion, we have established pre-negotiated prices, terms, deliverables, warranties and other details to aid in making the purchasing process more straightforward. Our Company is starting to realize the benefits of our partnership with Academy Medical with being able to service new distribution channels as well as increased revenue.”
About Endonovo
About
Academy Medical is a premier Service-Disabled Veteran-Owned Small Business and distributor of medical-surgical equipment and supplies to the Federal government. As a government procurement partner with industry expertise and access to advanced technology, Academy Medical’s mission is to leverage its preferred status as an SDVOSB to create a streamlined, more cost-effective process for its government customers and supplier partners.
Academy Medical is headquartered in
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate", "believe", "plan", "estimate", "expect", "intend" and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the
Investor Relations Contact:
(800) 701-1223 Ext. 108
sbarnes@endonovo.com
www.endonovo.com
Media Contact:
(310) 804-7037
greg@gregmcandrews.com
Source:
2023 GlobeNewswire, Inc., source